JAMA – Current Issue


Blood heating and cooling machines used during heart bypass were linked to 20 cases of Mycobacterium chimaera in California patients in 2016, according to a CDC report. [...]

A rare 9-person outbreak of wound botulism in California was traced to use of black tar heroin, according to a CDC report. [...]

This 2019 Recommendation Statement from the US Preventive Services Task Force recommends that clinicians provide or refer pregnant and postpartum persons at increased risk of perinatal depression to counseling interventions, such as cognitive behavioral or interpersonal therapy (B recommendation). [...]

This systematic review to support the 2019 US Preventive Services Task Force Recommendation Statement on interventions to prevent perinatal depression summarizes published evidence on the benefits and harms of primary care–relevant interventions to prevent depression during pregnancy or up to 1 year after childbirth. [...]

In this narrative medicine essay a physician recalls the connections she has forged with patients through conversations about their tattoos and reveals how she considers herself tattooed with the narratives and experiences they’ve shared. [...]

So blank, so lulled,I lived the seasons like a forest;so lank, so mild,the days disguised a warfare harvest. [...]

This JAMA Patient Page explains the US Preventive Services Task Force’s 2019 recommendations to provide or refer pregnant and postpartum women at risk of perinatal depression to counseling interventions such as cognitive behavioral therapy and interpersonal therapy. [...]

This cohort study found that 90-day mortality following elective noncardiac surgery was higher among Veterans Affairs patients with symptomatic or asymptomatic heart failure and reduced left ventricular ejection fraction (LVEF) compared with patients without heart failure. [...]

This randomized clinical trial compares the effects of combination paracetamol (acetaminophen) and ibuprofen at full vs half strength vs either drug alone on 24-hour patient-controlled morphine consumption and 90-day serious adverse events after total hip arthroplasty (THA). [...]

In Reply Dr Rodríguez-Baño and colleagues comment that our findings, in which 30-day all-cause mortality was 12.3% (23/187) of patients randomized to piperacillin-tazobactam compared with 3.7% (7/191) randomized to meropenem, stand in contrast to retrospective observational studies in which outcomes were similar between the 2 groups. In any observational study, the choice of antimicrobial is made by the clinician and is affected by clinical impression of how sick the patient is. Not surprisingly [...]

In Reply Dr Dickinson raises the question as to why the USPSTF recommended screening for cervical cancer with cervical cytology every 3 years in women aged 21 to 29 years (A recommendation) rather than starting at age 25 years. In support of starting screening at a later age, he cites the low incidence of cervical cancer in younger women, a case-control study showing no benefit in screening women aged 22 to 24 years vs 25 to 29 years, and clinical data from Wales reporting follow-up testing rate [...]

To the Editor Dr Harris and colleagues conducted a well-designed study investigating whether carbapenems for extended-spectrum β-lactamase–producing enterobacteria could be spared. The results should be interpreted with caution. [...]

To the Editor The MERINO trial found that piperacillin-tazobactam did not result in noninferior 30-day mortality in patients with Escherichia coli or Klebsiella pneumoniae bloodstream infections and ceftriaxone resistance, compared with meropenem. We think there might be reasons to explain the results other than differences in effectiveness of the antibiotic regimens. [...]

To the Editor The US Preventive Services Task Force (USPSTF) recently recommended screening for cervical cancer every 3 years with cervical cytology in women aged 21 to 29 years (A recommendation). I question why cervical screening is recommended starting at age 21 years rather than 25 years. For unscreened women younger than 25 years, the incidence of invasive cervical cancer is extremely low. Many other countries with evidence-based national policies start screening at age 25 years or even 30 [...]